STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD
---------------------------------------------------------------------------------------------------------------------
IN THE MATTER OF RULE-MAKING : AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE : ORDER OF THE
CONTROLLED SUBSTANCES BOARD : CONTROLLED SUBSTANCES BOARD
---------------------------------------------------------------------------------------------------------------------
FINDINGS
1. On January 31, 2020, the Department of Justice, Drug Enforcement Administration published its interim final rule in the Federal Register placing lasmiditan into schedule V of the federal Controlled Substances Act. The scheduling action is effective January 31, 2020.
2. The Controlled Substances Board did not receive an objection to similarly treating lasmiditan as a schedule V under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order designating lasmiditan as a controlled substance. 3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.21 and omitting the notice of proposed rule making, designating lasmiditan as a schedule V controlled substance. ORDER
Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats lasmiditan under chapter 961, Stats. by creating the following: CSB 2.71 Addition of lasmiditan to schedule V. Section 961.22(8), Stats., is created to read: 961.22 (8) Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide]
This order shall take effect on March 23, 2020 to allow for publication in the Administrative Register. The order expires upon promulgation of a final rule.
Dated March 13, 2020 
Doug Englebert, Chair
Controlled Substances Board
